237 related articles for article (PubMed ID: 28271215)
21. Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer.
Ishii K; Ogino R; Hosokawa Y; Fujioka C; Okada W; Nakahara R; Kawamorita R; Tada T; Hayashi Y; Nakajima T
Br J Radiol; 2016 Jun; 89(1062):20150930. PubMed ID: 26959612
[TBL] [Abstract][Full Text] [Related]
22. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome.
Fonteyne V; Lumen N; Ost P; Van Praet C; Vandecasteele K; De Gersem Ir W; Villeirs G; De Neve W; Decaestecker K; De Meerleer G
Radiother Oncol; 2013 Nov; 109(2):229-34. PubMed ID: 24016677
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant volumetric-modulated arc therapy with simultaneous integrated boost in endometrial cancer. Planning and toxicity comparison.
Macchia G; Cilla S; Morganti AG; Deodato F; Legge F; Piermattei A; Chiantera V; Scambia G; Valentini V; Ferrandina G
Acta Oncol; 2014 Feb; 53(2):251-8. PubMed ID: 24050516
[TBL] [Abstract][Full Text] [Related]
24. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.
Mazzola R; Fersino S; Fiorentino A; Ricchetti F; Giaj Levra N; Di Paola G; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Clin Transl Oncol; 2016 Mar; 18(3):317-21. PubMed ID: 26250766
[TBL] [Abstract][Full Text] [Related]
25. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy.
Pasquier D; Cavillon F; Lacornerie T; Touzeau C; Tresch E; Lartigau E
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):549-54. PubMed ID: 22677369
[TBL] [Abstract][Full Text] [Related]
26. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
27. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
[TBL] [Abstract][Full Text] [Related]
28. Volumetric-modulated arc therapy with vaginal cuff simultaneous integrated boost as an alternative to brachytherapy in adjuvant irradiation for endometrial cancer: a prospective study.
Alongi F; Mazzola R; Ricchetti F; Fersino S; Levra NG; Fiorentino A; Naccarato S; Sicignano G; Di Paola G; Ruggieri R; Gori S; Ceccaroni M
Anticancer Res; 2015 Apr; 35(4):2149-55. PubMed ID: 25862871
[TBL] [Abstract][Full Text] [Related]
29. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
30. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
[TBL] [Abstract][Full Text] [Related]
31. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity.
Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N
Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090
[TBL] [Abstract][Full Text] [Related]
32. Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis.
Tamihardja J; Schortmann M; Lawrenz I; Weick S; Bratengeier K; Flentje M; Guckenberger M; Polat B
Strahlenther Onkol; 2021 Feb; 197(2):124-132. PubMed ID: 32833036
[TBL] [Abstract][Full Text] [Related]
33. Ultra hypofractionated extended nodal irradiation using volumetric modulated arc therapy for oligorecurrent pelvic nodal prostate cancer.
Slevin F; Thompson CM; Speight R; Murray LJ; Lilley J; Henry AM
Med Dosim; 2021 Winter; 46(4):411-418. PubMed ID: 34148727
[TBL] [Abstract][Full Text] [Related]
34. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
35. Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity.
Engels B; Soete G; Tournel K; Bral S; De Coninck P; Verellen D; Storme G
Technol Cancer Res Treat; 2009 Oct; 8(5):353-59. PubMed ID: 19754211
[TBL] [Abstract][Full Text] [Related]
36. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.
Alongi F; Cozzi L; Fogliata A; Iftode C; Comito T; Clivio A; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Tomatis S; Taverna G; Graziotti P; Scorsetti M
Anticancer Res; 2013 Oct; 33(10):4537-43. PubMed ID: 24123027
[TBL] [Abstract][Full Text] [Related]
37. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results.
De Rose F; Fogliata A; Franceschini D; Navarria P; Villa E; Iftode C; D'Agostino G; Cozzi L; Lobefalo F; Mancosu P; Tomatis S; Scorsetti M
Radiat Oncol; 2016 Sep; 11(1):120. PubMed ID: 27639373
[TBL] [Abstract][Full Text] [Related]
39. Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: a dose-escalation trial.
Ippolito E; Cellini N; Digesù C; Cilla S; Mantini G; Balducci M; Di Lallo A; Deodato F; Macchia G; Massaccesi M; Mattiucci GC; Tagliaferri L; Piermattei A; Cuscunà D; Morganti AG
Urol Oncol; 2013 Jan; 31(1):87-92. PubMed ID: 21458315
[TBL] [Abstract][Full Text] [Related]
40. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
